ERYP - イライテック・ファ―マ (Erytech Pharma S.A.) イライテック・ファ―マ

 ERYPのチャート


 ERYPの企業情報

symbol ERYP
会社名 Erytech Pharma SA (イライテック・ファ―マ)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Biological Products (No Diagnostic Substances)  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 エレテック・ファルマ(ERYtech Pharma SA)は、腫瘍学・血液学・免疫学分野で医薬品を開発するフランスのバイオ医薬品会社。同社は、人間の相同赤血球に取り込まるL-アスパラギナーゼからなる医薬品であるESY-ASP(GRASPA)を提供する。その製品は、急性リンパ性白血病(ALL)である小児がんの治療に使用される。   イライテック・ファ―マはフランスの製薬会社。主にがん治療法の開発に従事する。独自の技術は治療分子を赤血球に封入することに基づき、同社開発の「ERY-ASP」は急性白血病の虚弱患者を治療するソリュ―ションを提供する。同社はOrphan Europe-RecordatiとTEVAグル―プと流通パ―トナ―シップを結ぶ。生産部門と本社所在地はリヨン。   
本社所在地 Batiment Adenine 60 Avenue Rockefeller Lyon 69008 FRA
代表者氏名
代表者役職名
電話番号
設立年月日 38261
市場名 NASDAQ National Market System
ipoyear 2017年
従業員数 116人
url www.erytech.com
nasdaq_url https://www.nasdaq.com/symbol/eryp
adr_tso 5017147
EBITDA EBITDA ー
終値(lastsale) 9.2255
時価総額(marketcap) 46285689.6485
時価総額 時価総額 ―
売上高 売上高 --
企業価値(EV) 企業価値(EV) ー
当期純利益 当期純利益 --
決算概要 決算概要 --

 ERYPのテクニカル分析


 ERYPのニュース

   63 Biggest Movers From Friday  2021/08/02 09:13:12 Business Insider Markets
Gainers ERYTECH Pharma S.A. (NASDAQ: ERYP ) shares surged 55% to close at $6.37 on Friday after the company
   Thinking about buying stock in Erytech Pharma, NanoVibronix, Atossa Therapeutics, Allied Healthcare, or Camber Energy?  2021/07/30 14:55:00 Benzinga
NEW YORK , July 30, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ERYP, NAOV, ATOS, AHPI, and CEI. Full story available on Benzinga.com
   ERYP Stock: The Huge FDA News That Has Little-Known Erytech Skyrocketing  2021/07/30 14:25:55 InvestorPlace
ERYP stock is seeing a surge in value this morning, as it lands FDA fast track designation for its eryaspase treatment for a second time.
   The Daily Biotech Pulse: Merck''s Disappointing Q2, Atreca Falls On Data, FDA Nod For Viatris, Nuvalent, Icosavax IPOs  2021/07/29 12:15:52 Benzinga
Here''s a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 28) AbbVie Inc. (NYSE: ABBV ) Alkermes plc (NASDAQ: ALKS ) (reacted to second-quarter results) Arvinas, Inc. (NASDAQ: ARVN ) Bio-Rad Laboratories, Inc. (NYSE: BIO ) BioNTech SE (NASDAQ: BNTX ) (reacted to COVID-19 vaccine sales revealed by Pfizer, Inc. in its quarterly results) Cassava Sciences, Inc. (NASDAQ: SAVA ) (saw an acceleration in momentum set in motion by Alzheimer''s data release) Edwards Lifesciences Corporation (NYSE: EW ) Globus Medical, Inc. (NYSE: GMED ) Horizon Therapeutics Public Limited Company (NASDAQ: HZNP ) Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD ) Merit Medical Systems, Inc. (NASDAQ: MMSI ) Repligen Corporation (NASDAQ: RGEN ) (reacted to second-quarter results) ResMed Inc. (NYSE: RMD ) West Pharmaceutical Services, Inc. (NYSE: WST ) Translate Bio, Inc. (NASDAQ: TBIO ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows July 28) 89bio, Inc. (NASDAQ: ETNB ) Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS ) Adicet Bio, Inc. (NASDAQ: ACET ) Aerovate Therapeutics, Inc. (NASDAQ: AVTE ) Biodesix, Inc. (NASDAQ: BDSX ) Candel Therapeutics, Inc.
   Acute Lymphoblastic Leukemia Therapeutics Market 2021 SWOT Analysis, Competitive Landscape and Significant Growth | Top Brands:Erytech Pharma, Spectrum Pharmaceuticals, Pfizer, Sigma-Tau, Shire, Ge  2021/07/25 12:43:04 Jumbo News
This report studies the Acute Lymphoblastic Leukemia Therapeutics Market with many aspects of the industry such as market size, market status, market trends and forecast. The report also provides brief information on competitors and opportunities for specific growth with the key market drivers. Find the comprehensive analysis of the Acute Lymphoblastic Leukemia Therapeutics market segmented []
   The Daily Biotech Pulse: Galapagos Sinks On Data, J&J Recalls Sunscreen Products, FibroGen Awaits AdCom Verdict, 3 IPOs  2021/07/15 12:07:56 Benzinga
Here''s a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 14) Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN ) - U.K. antitrust regulators cleared its pending acquisition by AstraZeneca PLC (NASDAQ: AZN ) Bristol-Myers Squibb Company (NYSE: BMY ) Celldex Therapeutics, Inc. (NASDAQ: CLDX ) Moderna, Inc. (NASDAQ: MRNA ) PLx Pharma Inc. (NASDAQ: PLXP ) Zoetis Inc. (NYSE: ZTS ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows July 14) 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT ) 89bio, Inc. (NASDAQ: ETNB ) AbCellera Biologics Inc. (NASDAQ: ABCL ) Achilles Therapeutics plc (NASDAQ: ACHL ) Adicet Bio, Inc. (NASDAQ: ACET ) Adverum Biotechnologies, Inc. (NASDAQ: ADVM ) Akero Therapeutics, Inc. (NASDAQ: AKRO ) Allena Pharmaceuticals, Inc. (NASDAQ: ALNA ) ( announced a registered direct offering) Allogene Therapeutics, Inc. (NASDAQ: ALLO ) AlloVir, Inc. (NASDAQ: ALVR ) Aptose Biosciences Inc. (NASDAQ: APTO ) Avenue Therapeutics, Inc.
   ERYTECH PHARMA (FR0011471135) : COMPTE RENDU - ASSEMBLEE GENERALE MIXTE DERYTECH LE 25 JUIN 2021  2021/06/25 20:30:00 Les Echos Company News
   Report - Erytech''s Combined Shareholders'' Meeting on June 25, 2021  2021/06/25 20:30:00 Benzinga
REPO R T - ERYTECH''S COMBINED SHAREHOLDERS'' MEE TING ON JUNE 25, 2021 SS RELEASE Lyon (France), June 2 5 , 2021 ERYTECH Pharma (NASDAQ: ERYP ) announced that its 202 1 Annual General Meeting was held in Lyon on Friday, June 25 , 2021 . At the meeting, all resolutions for which the Board of Directors recommended a vote in favor were adopted, including: - Approval of the annual financial statements and consolidated financial statements for the year ended December 31, 2020; - Allocation of the financial year''s results; - Approval of the statutory auditors'' special report on regulated agreements and commitments with related parties; - Approval of the elements of total compensation and benefits paid or allocated for the year ended December 31, 2020 to Gil BEYEN and Jean-Paul KRESS; - Approval of the compensation policy for executive corporate officers and board members; - Approval of the share subscription and/or purchase options plan adopted by the Board of Directors on July 28, 2020; - Delegations of authority to the Board of Directors to issue shares or other marketable securities convertible into shares to be issued immediately or in the future by the Company, with or without preferential subscription rights for the shareholders; - Authorization for the Board of Directors to grant free shares, share subscription and/or share purchase options and/or to issue share subscription warrants to corporate officers and employees of the Company or companies in
   ERYTECH PHARMA (FR0011471135) : ASSEMBLEE GENERALE MIXTE DERYTECH LE 25 JUIN 2021  2021/05/25 20:00:00 Les Echos Company News
   Phenylketonuria Treatment Market Analysis Released in Latest Industry Report 2020: BioMarin, Codexis, Erytech Pharma, SOM Innovation Biotech, Retrophin  2021/02/26 08:08:42 OpenPR
Global Phenylketonuria Treatment Market Analysis to 2027 is a specialized and in-depth study of the pharmaceutical industry with a special focus on the global market trend analysis. The report aims to provide an overview of Phenylketonuria Treatment market with detailed
   ERYTECH to Present at the H.C. Wainwright Virtual BioConnect 2021 Conference  2021/01/06 21:30:00 GlobeNewswire
ERYTECH to Present at the H.C. Wainwright Virtual BioConnect 2021 Conference Lyon (France) and Cambridge, MA (U.S.), January 6, 2021 – ERYTECH Pharma…
   ERYTECH Announces Positive Results from Eryaspase Phase 2 Trial in Acute Lymphoblastic Leukemia Presented at the American Society of Hematology Annual Meeting - Stocks News Feed  2020/12/07 07:00:00 Stocks News Feed
Webcast today, Monday, December 7at 4:00 pm CET/10:00 am ET The study confirms the potential of eryaspase as an attractive treatment option for ALL patients with hypersensitivity to PEG-asparaginase LYON, France and CAMBRIDGE, Mass., Dec. 07, 2020 (GLOBE NEWSWIRE) — ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating… Read More »ERYTECH Announces Positive Results from Eryaspase Phase 2 Trial in Acute Lymphoblastic Leukemia Presented at the American Society of Hematology Annual Meeting
   Erytech Pharma ADR Quartalszahlen: Gewinnerwartung und Umsatzprognose im Q3 entspricht dem Konsens  2020/11/06 00:00:00 Investing.com Germany
Erytech Pharma ADR Quartalszahlen: Gewinnerwartung und Umsatzprognose im Q3 entspricht dem Konsens
   ERYTECH secures €10M in non-dilutive financing (NASDAQ:ERYP)  2020/11/02 10:04:03 Seeking Alpha
ERYTECH Pharma (NASDAQ:ERYP) has received approval for for a total of €10M in non-dilutive financing from Bpifrance and Société Générale in the form of St

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 イライテック・ファ―マ ERYP Erytech Pharma S.A.)

 twitter  (公式ツイッターやCEOツイッターなど)